NASDAQ:IMACIMAC Stock Price, Forecast & News

IMAC's stock was trading at $0.82 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, IMAC stock has increased by 48.8% and is now trading at $1.22. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IMAC in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for IMAC.

IMAC is scheduled to release its next quarterly earnings announcement on Friday, August 21st 2020. View our earnings forecast for IMAC.

IMAC Holdings Inc (NASDAQ:IMAC) issued its earnings results on Thursday, May, 14th. The company reported ($0.18) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.01. The business earned $3.32 million during the quarter, compared to the consensus estimate of $5.72 million. IMAC had a negative return on equity of 80.08% and a negative net margin of 41.20%. View IMAC's earnings history.

2 Wall Street analysts have issued 1-year target prices for IMAC's stock. Their forecasts range from $4.50 to $4.50. On average, they expect IMAC's stock price to reach $4.50 in the next year. This suggests a possible upside of 268.9% from the stock's current price. View analysts' price targets for IMAC.

News articles about IMAC stock have been trending positive recently, according to InfoTrie Sentiment. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. IMAC earned a coverage optimism score of 3.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about IMAC.

IMAC saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 99,400 shares, an increase of 18.1% from the June 15th total of 84,200 shares. Based on an average trading volume of 1,030,000 shares, the short-interest ratio is presently 0.1 days. Approximately 1.6% of the company's shares are short sold. View IMAC's Current Options Chain.

Some companies that are related to IMAC include Acadia Healthcare (ACHC), BioTelemetry (BEAT), Hanger (HNGR), Biocorrx (BICX) and AAC (AAC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other IMAC investors own include NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Amarin (AMRN), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Aytu Bioscience (AYTU), Crispr Therapeutics (CRSP), Vaxart (VXRT), Agile Therapeutics (AGRX) and Armata Pharmaceuticals (ARMP).

(IMAC) raised $4 million in an IPO on the week of February 11th 2019. The company issued 900,000 shares at a price of $5.00 per share. Dawson James Securities and Cuttone served as the underwriters for the IPO.

IMAC trades on the NASDAQ under the ticker symbol "IMAC."

Shares of IMAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IMAC stock can currently be purchased for approximately $1.22.

IMAC has a market capitalization of $12.21 million and generates $15.13 million in revenue each year. The company earns $-6,500,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis.

The official website for IMAC is www.imacregeneration.com.

IMAC's mailing address is 1605 WESTGATE CIRCLE, BRENTWOOD TN, 37027. The company can be reached via phone at 844-266-4622 or via email at [email protected]